Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Sales (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Return on Sales for 6 consecutive years, with 101.9% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales fell 5978.0% year-over-year to 101.9%, compared with a TTM value of 120.17% through Sep 2025, up 3256.0%, and an annual FY2024 reading of 4.09%, up 8749.0% over the prior year.
  • Return on Sales was 101.9% for Q3 2025 at Barinthus Biotherapeutics, up from 21126.0% in the prior quarter.
  • Across five years, Return on Sales topped out at 16837.0% in Q4 2021 and bottomed at 21126.0% in Q2 2025.
  • Average Return on Sales over 5 years is 154.99%, with a median of 11.39% recorded in 2023.
  • The sharpest move saw Return on Sales surged 1683750bps in 2021, then plummeted -2078265bps in 2025.
  • Year by year, Return on Sales stood at 16837.0% in 2021, then crashed by -100bps to 3.28% in 2022, then skyrocketed by 75462bps to 2470.0% in 2023, then plummeted by -105bps to 119.72% in 2024, then grew by 15bps to 101.9% in 2025.
  • Business Quant data shows Return on Sales for BRNS at 101.9% in Q3 2025, 21126.0% in Q2 2025, and 62.21% in Q1 2025.